Join Growin Stock Community!

Terns pharmaceuticals, inc.TERN.US Overview

US StockHealthcare
(No presentation for TERN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TERN AI Insights

TERN Overall Performance

TERN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TERN Recent Performance

-0.15%

Terns pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

TERN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TERN Key Information

TERN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TERN Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Price of TERN

TERN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TERN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.05
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
302.64
PB Ratio
16.13
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.05
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
302.64
PB Ratio
16.13
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is TERN's latest earnings report released?

    The most recent financial report for Terns pharmaceuticals, inc. (TERN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TERN's short-term business performance and financial health. For the latest updates on TERN's earnings releases, visit this page regularly.

  • How much debt does TERN have?

    As of the end of the reporting period, Terns pharmaceuticals, inc. (TERN) had total debt of 1.03M, with a debt ratio of 0. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TERN have?

    At the end of the period, Terns pharmaceuticals, inc. (TERN) held Total Cash and Cash Equivalents of 150.7M, accounting for 0.5 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TERN's EPS continuing to grow?

    According to the past four quarterly reports, Terns pharmaceuticals, inc. (TERN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TERN?

    Terns pharmaceuticals, inc. (TERN)'s Free Cash Flow (FCF) for the period is -19.77M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 20.16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.